Progress of Legumain in malignant tumors

Abstract

Yan Bingfang, Meng Wei, Bai Xuelian. Progress of Legumain in malignant tumors[J]. Journal of International Oncology, 2020, 47(9): 546-549.

References36

[1]	Kembhavi AA, Buttle DJ, Knight CG, et al. The two cysteine endopeptidases of legume seeds: purification and characterization by use of specific assays[J]. Arch Biochem Biophys, 1993,303(2):208-213. DOI: 10.1006/abbi.1993.1274. doi:10.1006/abbi.1993.1274pmid:8512309
[2]	Liu C, Sun C, Huang H, et al. Overexpression of Legumain in tumors is significant for invasion/metastasis and a candidate enzymatic target for prodrug therapy[J]. Cancer Res, 2003,63(11):2957-2964. DOI: 10.1097/00002820-200306000-00012. pmid:12782603
[3]	Dall E, Brandstetter H. Structure and function of Legumain in health and disease[J]. Biochimie, 2016,122:126-150. DOI: 10.1016/j.biochi.2015.09.022. doi:10.1016/j.biochi.2015.09.022pmid:26403494
[4]	Lunde NN, Haugen MH, Bodin Larsen KB, et al. Glycosylation is important for Legumain localization and processing to active forms but not for cystatin E/M inhibitory functions[J]. Biochimie, 2017,139:27-37. DOI: 10.1016/j.biochi.2017.05.009. doi:10.1016/j.biochi.2017.05.009pmid:28528272
[5]	Lin S, Li T, Xie P, et al. Targeted delivery of doxorubicin to tumour tissues by a novel Legumain sensitive polygonal nanogel[J]. Nanoscale, 2016,8(43):18400-18411. DOI: 10.1039/c6nr05870a. doi:10.1039/c6nr05870apmid:27774557
[6]	Jafari A, Qanie D, Andersen TL, et al. Legumain regulates differentiation fate of human bone marrow stromal cells and is altered in postmenopausal osteoporosis[J]. Stem Cell Reports, 2017,8(2):373-386. DOI: 10.1016/j.stemcr.2017.01.003. doi:10.1016/j.stemcr.2017.01.003pmid:28162997
[7]	Hasegawa S, Inoue D, Yamasaki M, et al. Site-specific cleavage of acetoacetyl-CoA synthetase by Legumain[J]. FEBS Lett, 2016,590(11):1592-1601. DOI: 10.1002/1873-3468.12197. doi:10.1002/1873-3468.12197pmid:27129883
[8]	Anderson BM, de Almeida LGN, Sekhon H, et al. N-terminomics/TAILS profiling of macrophages after chemical inhibition of Legumain[J]. Biochemistry, 2019,59(3):329-340. DOI: 10.1021/acs.biochem.9b00821. doi:10.1021/acs.biochem.9b00821pmid:31774660
[9]	Wang D, Xiong M, Chen C, et al. Legumain, an asparaginyl endopeptidase, mediates the effect of M2 macrophages on attenuating renal interstitial fibrosis in obstructive nephropathy[J]. Kidney Int, 2018,94(1):91-101. DOI: 10.1016/j.kint.2017.12.025. doi:10.1016/j.kint.2017.12.025pmid:29656902
[10]	Meng F, Liu W. Knockdown of Legumain suppresses cervical cancer cell migration and invasion[J]. Oncol Res, 2016,23(1):7-12. DOI: 10.3727/096504015X14410238486649. doi:10.3727/096504015X14410238486649pmid:29021015
[11]	Wu T, Sun L, Wu Y, et al. Prognostic value of Legumain in uveal melanoma[J]. Mol Med Rep, 2016,13(3):2377-2384. DOI: 10.3892/mmr.2016.4838. doi:10.3892/mmr.2016.4838pmid:26846877
[12]	Haugen MH, Boye K, Nesland JM, et al. High expression of the cysteine proteinase Legumain in colorectal cancer-implications for therapeutic targeting[J]. Eur J Cancer, 2015,51(1):9-17. DOI: 10.1016/j.ejca.2014.10.020. doi:10.1016/j.ejca.2014.10.020pmid:25466510
[13]	Wang H, Chen B, Lin Y, et al. Legumain promotes gastric cancer progression through tumor-associated macrophages in vitro and in vivo[J]. Int J Biol Sci, 2020,16(1):172-180. DOI: 10.7150/ijbs.36467. doi:10.7150/ijbs.36467pmid:31892854
[14]	Luo M, Li Q, Wang D, et al. Fabrication of chitosan based nanocomposite with Legumain sensitive properties using charge driven self-assembly strategy[J]. J Mater Sci Mater Med, 2018,29(9):142. DOI: 10.1007/s10856-018-6149-y. doi:10.1007/s10856-018-6149-ypmid:30121849
[15]	Zhang M, Jiang Z, Chen S, et al. Legumain correlates with neuroblastoma differentiation and can be used in prodrug design[J]. Chem Biol Drug Des, 2018,91(2):534-544. DOI: 10.1111/cbdd.13116. doi:10.1111/cbdd.13116pmid:28994241
[16]	Wang L, Chen S, Zhang MN, et al. Legumain: a biomarker for diagnosis and prognosis of human ovarian cancer[J]. J Cell Biochem, 2012,113(8):2679-2686. DOI: 10.1002/jcb.24143. doi:10.1002/jcb.24143pmid:22441772
[17]	杜祎祎. Legumain通过PI3K/AKT通路促进乳腺癌侵袭和转移的研究[D]. 天津: 天津医科大学, 2019. DOI: 10.27366/d.cnki.gtyku.2019.000313.
[18]	Murthy RV, Arbman G, Gao J, et al. Legumain expression in relation to clinicopathologic and biological variables in colorectal cancer[J]. Clin Cancer Res, 2005,11(6):2293-2299. DOI: 10.1158/1078-0432.ccr-04-1642. doi:10.1158/1078-0432.CCR-04-1642pmid:15788679
[19]	Zhen Y, Chunlei G, Wenzhi S, et al. Clinicopathologic significance of Legumain overexpression in cancer: a systematic review and meta-analysis[J]. Sci Rep, 2015,5:16599. DOI: 10.1038/srep16599. doi:10.1038/srep16599pmid:26607955
[20]	Toss MS, Miligy IM, Gorringe KL, et al. Legumain is an indepen-dent predictor for invasive recurrence in breast ductal carcinoma in situ[J]. Mod Pathol, 2019,32(5):639-649. DOI: 10.1038/s41379-018-0180-x. doi:10.1038/s41379-018-0180-xpmid:30429518
[21]	Shen L, Li H, Shi Y, et al. M2 tumour-associated macrophages contribute to tumour progression via Legumain remodelling the extracellular matrix in diffuse large B cell lymphoma[J]. Sci Rep, 2016,6:30347. DOI: 10.1038/srep30347. doi:10.1038/srep30347pmid:27464733
[22]	Andrade V, Guerra M, Jardim C, et al. Nucleoplasmic calcium regulates cell proliferation through Legumain[J]. J Hepatol, 2011,55(3):626-635. DOI: 10.1016/j.jhep.2010.12.022. doi:10.1016/j.jhep.2010.12.022pmid:21237226
[23]	Liu Y, Goswami RK, Liu C, et al. Chemically programmed bispecific antibody targeting Legumain protease and αvβ3 integrin mediates strong antitumor effects[J]. Mol Pharm, 2015,12(7):2544-2550. DOI: 10.1021/acs.molpharmaceut.5b00257. doi:10.1021/acs.molpharmaceut.5b00257pmid:26024761
[24]	Cui Y, Wang Y, Li H, et al. Asparaginyl endopeptidase promotes the invasion and metastasis of gastric cancer through modulating epithelial-to-mesenchymal transition and analysis of their phosphorylation signaling pathways[J]. Oncotarget, 2016,7(23):34356-34370. DOI: 10.18632/oncotarget.8879. doi:10.18632/oncotarget.8879pmid:27102302
[25]	Zhang Y, Wu YY, Jiang JN, et al. MiRNA-3978 regulates peritoneal gastric cancer metastasis by targeting Legumain[J]. Oncotarget, 2016,7(50):83223-83230. DOI: 10.18632/oncotarget.12917. doi:10.18632/oncotarget.12917pmid:27793040
[26]	Yamane T, Murao S, Kato-Ose I, et al. Transcriptional regulation of the legumain gene by p53 in HCT116 cells[J]. Biochem Biophys Res Commun, 2013,438(4):613-618. DOI: 10.1016/j.bbrc.2013.08.007. doi:10.1016/j.bbrc.2013.08.007pmid:23942113
[27]	Yamane T, Yamamoto Y, Nakano Y, et al. Expression and protease activity of mouse Legumain are regulated by the oncogene/transcription co-activator, DJ-1 through p53 and cleavage of annexin A2 is increased in DJ-1-knockout cells[J]. Biochem Biophys Res Commun, 2015,467(3):472-477. DOI: 10.1016/j.bbrc.2015.10.032. doi:10.1016/j.bbrc.2015.10.032pmid:26462467
[28]	Yamane T, Kato-Ose I, Sakamoto T, et al. Secretion of Legumain increases in conditioned medium from DJ-1-knockout cells and in serum from DJ-1-knockout mice[J]. Open Biochem J, 2018,12:29-35. DOI: 10.2174/1874091X01812010029. doi:10.2174/1874091X01812010029pmid:29541256
[29]	Rawlings ND, Barrett AJ, Bateman A. MEROPS: the database of proteolytic enzymes, their substrates and inhibitors[J]. Nucleic Acids Res, 2012,40:D343-D350. DOI: 10.1093/nar/gkt987. doi:10.1093/nar/gkr987pmid:22086950
[30]	Yamane T, Kozuka M, Yamamoto Y, et al. Protease activity of Legumain is inhibited by an increase of cystatin E/M in the DJ-1-knockout mouse spleen, cerebrum and heart[J]. Biochem Biophys Rep, 2017,9:187-192. DOI: 10.1016/j.bbrep.2016.12.010. doi:10.1016/j.bbrep.2016.12.010pmid:28956004
[31]	Lerchen HG, Stelte-Ludwig B, Berndt S, et al. Antibodye-prodrug conjugates with ksp inhibitors and Legumain-mediated metabolite formation[J]. Chemistry, 2019,25(35):8208-8213. DOI: 10.1002/chem.201900441. pmid:30869180
[32]	Shi T, Gu L, Sun Y, et al. Enhanced Legumain-recognition and NIR controlled released of cisplatin-indocyanine nanosphere against gastric carcinoma[J]. Eur J Pharmacol, 2017,794:184-192. DOI: 10.1016/j.ejphar.2016.11.039. doi:10.1016/j.ejphar.2016.11.039pmid:27894812
[33]	Li Y, Niu Y, Zhu J, et al. Tailor-made Legumain/pH dual-responsive doxorubicin prodrug-embedded nanoparticles for efficient anticancer drug delivery and in situ monitoring of drug release[J]. Nanoscale, 2020,12(4):2673-2685. DOI: 10.1039/c9nr08558k. doi:10.1039/C9NR08558Kpmid:31942900
[34]	Eddie SL, Gregson A, Graham E, et al. Identification and SAR exploration of a novel series of Legumain inhibitors[J]. Bioorg Med Chem Lett, 2019,29(12):1546-1548. DOI: 10.1016/j.bmcl.2019.03.019. doi:10.1016/j.bmcl.2019.03.019pmid:31005445
[35]	Li X, Liu Q, Ye S, et al. A protease-responsive fluorescent probe for sensitive imaging of Legumain activity in tumor cells[J]. Chem Biol Drug Des, 2019,94(2):1494-1503. DOI: 10.1111/cbdd.13530. doi:10.1111/cbdd.13530pmid:31002467
[36]	Zhao Y, Hai Z, Wang H, et al. Legumain-specific near-infrared fluorescence “turn on” for tumor-targeted imaging[J]. Anal Chem, 2018,90(15):8732-8735. DOI: 10.1021/acs.analchem.8b02704. doi:10.1021/acs.analchem.8b02704pmid:30027744

RichHTML

PDF

Knowledge

Abstract

Cite this article

share this article

References36

Related Articles15

Recommended Articles

Metrics

Comments

[1]	Liu Na, Kou Jieli, Yang Feng, Liu Taotao, Li Danping, Han Junrui, Yang Lizhou.Clinical value of serum miR-106b-5p and miR-760 combined with low-dose spiral CT in the diagnosis of early lung cancer[J]. Journal of International Oncology, 2024, 51(6): 321-325.
[2]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun.Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer[J]. Journal of International Oncology, 2024, 51(6): 332-337.
[3]	Yuan Jian, Huang Yanhua.Diagnostic value of Hp-IgG antibody combined with serum DKK1 and sB7-H3 in early gastric cancer[J]. Journal of International Oncology, 2024, 51(6): 338-343.
[4]	Chen Hongjian, Zhang Suqing.Study on the relationship between serum miR-24-3p， H2AFX and clinical pathological features and postoperative recurrence in liver cancer patients[J]. Journal of International Oncology, 2024, 51(6): 344-349.
[5]	Guo Zehao, Zhang Junwang.Role of PFDN and its subunits in tumorigenesis and tumor development[J]. Journal of International Oncology, 2024, 51(6): 350-353.
[6]	Zhang Baihong, Yue Hongyun.Advances in anti-tumor drugs with new mechanisms of action[J]. Journal of International Oncology, 2024, 51(6): 354-358.
[7]	Xu Fenglin, Wu Gang.Research progress of EBV in tumor immune microenvironment and immunotherapy of nasopharyngeal carcinoma[J]. Journal of International Oncology, 2024, 51(6): 359-363.
[8]	Wang Ying, Liu Nan, Guo Bing.Advances of antibody-drug conjugate in the therapy of metastatic breast cancer[J]. Journal of International Oncology, 2024, 51(6): 364-369.
[9]	Zhang Rui, Chu Yanliu.Research progress of colorectal cancer risk assessment models based on FIT and gut microbiota[J]. Journal of International Oncology, 2024, 51(6): 370-375.
[10]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu.Research progress on intestinal flora and non-surgical treatment of the colorectal cancer[J]. Journal of International Oncology, 2024, 51(6): 376-381.
[11]	Liu Jing, Liu Qin, Huang Mei.Prognostic model construction of lung infection in patients with chemoradiotherapy for esophageal cancer based on SMOTE algorithm[J]. Journal of International Oncology, 2024, 51(5): 267-273.
[12]	Yang Lin, Lu Ning, Wen Hua, Zhang Mingxin, Zhu Lin.Study on the clinical relationship between inflammatory burden index and gastric cancer[J]. Journal of International Oncology, 2024, 51(5): 274-279.
[13]	Wang Junyi, Hong Kaibin, Ji Rongjia, Chen Dachao.Effect of cancer nodules on liver metastases after radical resection of colorectal cancer[J]. Journal of International Oncology, 2024, 51(5): 280-285.
[14]	Zhang Ningning, Yang Zhe, Tan Limei, Li Zhenning, Wang Di, Wei Yongzhi.Diagnostic value of cervical cell DNA ploidy analysis combined with B7-H4 and PKCδ for cervical cancer[J]. Journal of International Oncology, 2024, 51(5): 286-291.
[15]	Fu Yi, Ma Chenying, Zhang Lu, Zhou Juying.Research progress of habitat analysis in radiomics of malignant tumors[J]. Journal of International Oncology, 2024, 51(5): 292-297.